Updated data show emavusertib plus ibrutinib achieves high response rates in both BTKI-naive and BTKI-experienced PCNSL patients, exceeding historical controls. Regulatory discussions support accelerated approval, and expansion into CLL and other NHL subtypes is underway.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.